Literature DB >> 25929203

Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.

Christopher K Kepler1, Dessislava Z Markova, John D Koerner, Joseph Mendelis, Chiu-Ming Chen, Alexander R Vaccaro, Makarand V Risbud, Todd J Albert, D Greg Anderson.   

Abstract

STUDY
DESIGN: Laboratory study.
OBJECTIVE: To evaluate whether blockade of the Substance P (SP) NK1R attenuates its proinflammatory effect on human intervertebral disc cells (IVD), and to evaluate the signaling pathways associated with SP. SUMMARY OF BACKGROUND DATA: SP and its receptors are expressed in human IVD cells, and cause upregulation of inflammatory mediators; however, the effects of blocking these receptors have not been studied in human IVD cells.
METHODS: Human annulus fibrosus (AF) and nucleus pulposus (NP) cells were expanded in monolayer, and then suspended in alginate beads. The alginate beads were treated with culture medium first containing a high affinity NK1R antagonist (L-760735) at different concentrations, and then with medium containing both NK1R antagonist and SP at 2 concentrations. Ribonucleic acid was isolated and transcribed into cDNA. Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to evaluate expression of interleukin (IL)-1β, IL-6, and IL-8. Western blot analysis was performed to examine levels of the phosphorylated p38 mitogen-activated protein kinase (MAPK), extracellular signal regulated kinase 1/2 (ERK1/2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB p65). The cells were pretreated with specific inhibitors of p38 (SB203580), ERK1/2 (PD98059), and p65 (SM7368) and then stimulated with SP.
RESULTS: We detected expression of NK1R, neurokinin receptor 2 (NK2R), and neurokinin receptor 3 (NK3R) in AF and NP cells. Treatment of disc cells with the NK1R antagonist was able to suppress expression of IL-1β, IL-6, and IL-8 in a dose-dependent manner. SP stimulation increased phosphorylation of p38-MAPK and ERK1/2, but not of NFκB p65. This indicates that p38-MAPK and ERK1/2 control SP-induced cytokine expression independently from NF-kB p65. Inhibition of p38 and ERK1/2 activation reduced SP-induced IL-6 production in human disc cells.
CONCLUSION: NK1R is responsible for the proinflammatory effect of SP on IVD cells and this effect can be blocked by preventing binding of SP to NK1R. This study shows for the first time that SP mediates signaling in disc cells through NK1R and that SP activates the proinflammatory p38-MAPK and ERK1/2 pathways. LEVEL OF EVIDENCE: 4.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25929203     DOI: 10.1097/BRS.0000000000000954

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  5 in total

Review 1.  Discovery of the drivers of inflammation induced chronic low back pain: from bacteria to diabetes.

Authors:  Deborah J Gorth; Irving M Shapiro; Makarand V Risbud
Journal:  Discov Med       Date:  2015-10       Impact factor: 2.970

2.  Neuropeptide Y prevents nucleus pulposus cells from cell apoptosis and IL‑1β‑induced extracellular matrix degradation.

Authors:  Kaiqiang Sun; Jian Zhu; Jingchuan Sun; Xiaofei Sun; Le Huan; Bin Zhang; Feng Lin; Bing Zheng; Jialin Jiang; Xi Luo; Ximing Xu; Jiangang Shi
Journal:  Cell Cycle       Date:  2021-05-08       Impact factor: 4.534

Review 3.  Cell-based strategies for IVD repair: clinical progress and translational obstacles.

Authors:  Abbie L A Binch; Joan C Fitzgerald; Emily A Growney; Frank Barry
Journal:  Nat Rev Rheumatol       Date:  2021-02-01       Impact factor: 32.286

4.  Substance P modulates electroacupuncture analgesia in humanized mice with sickle cell disease.

Authors:  Ying Wang; Jianxun Lei; Ritu K Jha; Stacy Kiven; Kalpna Gupta
Journal:  J Pain Res       Date:  2019-08-01       Impact factor: 3.133

5.  Combinatorial conditioning of adipose derived-mesenchymal stem cells enhances their neurovascular potential: Implications for intervertebral disc degeneration.

Authors:  Abbie L A Binch; Stephen M Richardson; Judith A Hoyland; Frank P Barry
Journal:  JOR Spine       Date:  2019-12-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.